Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation.
Xue-Jun GuoXiao-Ting CaiZi-Xuan RongYan-Pei ZhangYu-Xiang WenXue BaiJian WangQiang John FuZe-Qin GuoLi-Li LongSi-Cong MaXin-Ran TangLi LiuJian GuanZhong-Yi DongDe-Hua WuPublished in: BMC medicine (2023)
Compared with ICI monotherapy, ICI combined with RT, rather than with CHEMO or TARGET, is associated with a higher risk of IP in NSCLC patients. Hence, patients receiving these treatments should be carefully monitored for IP.
Keyphrases
- small cell lung cancer
- ejection fraction
- newly diagnosed
- combination therapy
- photodynamic therapy
- prognostic factors
- emergency department
- electronic health record
- clinical trial
- advanced non small cell lung cancer
- drug induced
- systemic sclerosis
- interstitial lung disease
- idiopathic pulmonary fibrosis
- data analysis